Skye Bioscience Receives Nasdaq Notice for Equity Non‑Compliance

What Happened
Skye Bioscience, Inc. (SKYE) announced that on August 18, 2026 it received a written notice from the Nasdaq Listing Qualifications Department informing the company it is not in compliance with Nasdaq Capital Market Rule 5550(b)(1) because its stockholders’ equity was reported as negative $497,307 for the quarter ended June 30, 2026. The notice does not currently affect trading — SKYE will continue to trade on the Nasdaq Capital Market under the symbol “SKYE.”

Key Details

• Nasdaq notice date: August 18, 2026; required minimum stockholders’ equity: $2,500,000.
• Reported stockholders’ equity (6/30/2026): ($497,307) — i.e., negative equity.
• Deadline to submit a plan to Nasdaq: 45 calendar days from the notice (until October 2, 2026).
• If Nasdaq accepts a plan, the company may be granted an extension up to 180 days from the notice (potential compliance deadline: February 14, 2027); if not accepted, the company may appeal and remain listed during the appeal.
• The filing also notes Skye’s planned acquisition of Redx Pharma Limited and that a proxy statement will be filed with the SEC in connection with that transaction.

Why It Matters
Nasdaq non-compliance notices signal a material listing risk: if Skye cannot restore at least $2.5 million in stockholders’ equity (or otherwise satisfy Nasdaq requirements), the company could face delisting proceedings. For investors, this raises potential liquidity and valuation concerns and could affect stock price and access to capital. Skye is evaluating options to regain compliance and has formal steps (plan submission, possible extension, or appeal) available; however, the filing cautions there is no assurance the company will succeed. The company also continues work on a proposed acquisition of Redx, which could affect future financials and the path to compliance; a proxy statement will be filed with more details.